Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical
testing, announces that it has raised total gross proceeds of c.
EUR 299 million following the issuance of 550,000 new shares to
institutional investors, at a price of EUR 543 per share,
representing a 3.0% discount to the closing price on 30th October,
2017, and no discount to the 1-month VWAP*.
Following strong investor demand, Eurofins’ management decided
to increase the offer size from 500,000 to 550,000 new shares to
secure greater funding flexibility for potential acquisitions. As
communicated in yesterday’s press release announcing the launch of
the equity offering, Eurofins intends to use proceeds from the
issuance towards financing identified potential acquisition
targets. These targets would represent opportunities that are over
and above the Group’s target acquisition program of EUR 200m per
year to reach its revenue objective of EUR 4bn by 2019. The
objective is that acquisitions create value for shareholders above
their acquisition cost.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
success of this equity issuance demonstrates investors’ confidence
in our ability to deploy capital to create significant shareholder
value. I would like to thank our supporters in the capital markets
for the trust that they have extended over the years, and continue
to give to Eurofins, and reiterate that the Board, and the
executive management of Eurofins, intend to invest with the same
disciplined approach that it has employed in the past, with the
objective to create higher earnings per share (EPS) than the
dilution impact from the new issuance.”
Berenberg and Jefferies acted as joint book-runners for the
Placement. The settlement-delivery and the admission of the new
shares on Euronext Paris (on the same line as Eurofins’ existing
shares (ISIN code FR0000038259) should occur on November 2nd,
2017.
*Volume Weighted Average Price
For more information, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 400 laboratories across 41 countries, Eurofins offers a
portfolio of over 150,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
This press release does not, and shall not, in any
circumstances, constitute a public offering nor an invitation in
any jurisdiction in connection with any offer.
In any Member State of the European Economic Area (“EEA”), this
press release is only addressed to and directed at persons in
Member States who are “qualified investors” within the meaning of
Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC,
as amended).
This press release has been prepared on the basis that any offer
of the new shares in any Member State of the EEA which has
implemented the Prospectus Directive, and in particular in the
Grand Duchy of Luxembourg and France, (each, a "Relevant Member
State") will be made pursuant to an exemption under the Prospectus
Directive, as implemented in that Relevant Member State, from the
requirement to publish a prospectus. Accordingly any person making
or intending to make any offer in that Relevant Member State of
securities which are the subject of the placement contemplated in
this press release may only do so in circumstances in which no
obligation arises for Eurofins Scientific or any of the Joint
Bookrunners to publish a prospectus pursuant to Article 3 of the
Prospectus Directive, as amended, in relation to such offer.
Neither Eurofins Scientific nor the Joint Bookrunners have
authorized, nor do they authorize, the making of any offer of the
new shares in circumstances in which an obligation arises for
Eurofins Scientific or any of the Joint Bookrunners to publish
prospectus for such offer.
This press release is only being distributed to, and is only
directed at, persons in the United Kingdom that (i) are “investment
professionals” falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (as
amended, the "Order"), (ii) are persons falling within Article
49(2)(a) to (d) ("high net worth companies, unincorporated
associations, etc.") of the Order, or (iii) are persons to whom an
invitation or inducement to engage in investment activity (within
the meaning of section 21 of the Financial Services and Markets Act
2000) in connection with the issue or sale of any securities may
otherwise lawfully be communicated or caused to be communicated
(all such persons together being referred to as "relevant
persons"). This press release is directed only at relevant persons
and must not be acted on or relied on by persons who are not
relevant persons. Any investment or investment activity to which
this press release relates is available only to relevant persons
and will be engaged in only with relevant persons.
This press release is an advertisement and not a prospectus for
the purposes of applicable measures implementing Directive
2003/71/EC, as amended.
This press release is not an offer of securities for sale nor
the solicitation of an offer to purchase securities in the United
States of America or any other jurisdiction. Securities may not be
offered or sold in the United States of America absent registration
or an exemption from registration under the U.S. Securities Act of
1933, as amended. Eurofins Scientific does not intend to register
any portion of the planned offering in the United States of America
or to conduct a public offering of securities in the United States
of America.
It may be unlawful to distribute these materials in certain
jurisdictions. These materials are not for distribution in the
United States, Canada, Japan or Australia. The information in these
materials does not constitute an offer of securities for sale in
the United States, Canada, Japan or Australia.
Each of the Joint Bookrunners involved in the Placement is
acting on behalf of Eurofins Scientific and no one else in
connection with any offering of the shares and will not be
responsible to any other person for providing the protections
afforded to any of its clients or for providing advice in relation
to any offering of Eurofins Scientific shares.
The Joint Bookrunners involved in the Placement and certain of
their affiliates, have provided and may in the future provide
various financing, banking, financial, investment, commercial or
other services to Eurofins Scientific or to members of its group,
in exchange for which they have received or may receive
compensation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171030006424/en/
Eurofins Scientific SEHugues Vaussy, +32-2-769 7383Head
of Corporate Communication and Investor
Relationsir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024